艾昆纬：2025年美国 340B 药品采购规模与增长分析报告：按标价采购额为1800亿-2000亿美元（英文版）（12页）.pdf

1、White PaperThe Size and Growth of the 340B Program in 2025 Estimated 340B purchases totaled$180-$200 billion at list prices RORY MARTIN,PhD,IQVIA Market Access Technology SolutionsHARISH KARNE,MS,IQVIA Market Access Technology SolutionsSHANYUE ZENG,MS,IQVIA Market Access Technology SolutionsTable of

2、 contentsAbstract 1Introduction 2Findings 3Channel trends 4Disease areas 5Discussion 6Data sources 7Limitations 7References 8About the authors 9Acknowledgements 9 |1AbstractThis study is part of an ongoing series by IQVIA that examines the size and growth of the 340B drug pricing program,and provide

3、s a descriptive estimate of the size,growth,and composition of the program.In 2025,340B purchases reached$179.5 billion at list prices,growing 20.3%year-over-year.From 2018 to 2025,340B purchases at list prices more than tripled in size and grew at three times the rate of the rest of the U.S.drug ma

4、rket.Adjusted for missing sales in our sample,we estimate that total program purchases at list prices were approximately$200 billion,which is approaching the size of medicare Part D.The hospital and clinic channels now account for almost three quarters of 340B purchases;and five disease areas target

5、ed oncology,immunology,anti-virals,diabetes,and anti-arthritics account for more than two thirds of program sales.The future growth of the 340B program may be influenced by additional states enacting contract pharmacy mandates and ambiguity in how some 340B providers interpret patient eligibility ru

6、les.In addition,policy factors will likely slow program growth,including maximum fair price effects and the possible introduction of a 340B rebate model which would increase transparency for the patient definition and reduce duplicate discounts.2|The Size and Growth of the 340B Program in 2025Introd